Technologies Sample Clauses

Technologies. Bitdefender informs you that in certain programs or products it may use data collection technology to collect technical information (including suspect files), to improve the products, to provide related services, to adapt them to the latest industry trends and to prevent the unlicensed or illegal use of the product or the damages resulting from the malware products. You accept that Bitdefender may use such information as part of the services provided in relation to the product and to prevent and stop the malware programs running on your device. By accepting this Agreement, You acknowledge and agree that the security technology used can scan the traffic in an impersonal mode to detect the malware and to prevent the damages resulting from the malware products. You acknowledge and accept that Bitdefender may provide updates or additions to the program or product which automatically download to your device. By accepting this Agreement, You agree that some of the executable files considered potentially harmful, may be submitted to Bitdefender servers for the purpose of being scanned. Bitdefender reserves the right to collect certain information from the computer on which it is installed, depending on the modules and services You have activated in your Bitdefender Solution. Such information may pertain to potential security risks as well as to URLs of websites visited that the Bitdefender Solution and Services deems potentially fraudulent. The URLs could contain personally identifiable information that a potentially fraudulent website is attempting to obtain without Your permission. As such, You agree that certain Product modules, services and components may collect pieces of data from your systems for the purpose of evaluating and improving the ability of Bitdefender’s products to detect malicious behavior, potentially fraudulent websites and other Internet security risks. Bitdefender also employs proprietary Cloud technologies to perform scanning on certain URLs, files or emails submitted from your systems.
AutoNDA by SimpleDocs
Technologies. The collaboration will leverage Cytokinetics' proprietary platform, Cytometrix(TM) cellular phenotyping technologies, which are routinely utilized in Cytokinetics' screening processes to analyze both on-target and off-target effects of candidate compounds. Cytometrix(TM) cellular phenotyping technologies utilize cell-based assays to create digital phenotypic profiles ("fingerprints") representative of diverse molecular mechanisms of drug action. Cytometrix(TM) fingerprints detail information on the potency and specificity of a compound or drug-related toxicities. Cytokinetics presently employs Cytometrix(TM) cellular phenotyping technologies to eliminate compounds of mixed mechanism, allowing the company to focus its medicinal chemistry and pharmacology resources more selectively on higher quality chemical series. This collaboration with AstraZeneca is designed to develop a new Cytometrix(TM) technologies application called the Cytometrix(TM) Hepatotoxicity Module for the in vitro prediction of hepatotoxicities downstream of screening. - more - ABOUT CYTOKINETICS Founded in 1998 and privately held, Cytokinetics is dedicated to the discovery, development and commercialization of a novel class of therapeutics resulting from its leadership position in the emerging field of cytoskeletal pharmacology. The cytoskeleton is a complex, dynamic framework that impacts all aspects of cell function including cell division, cell motility, intracellular transport, muscle contractility and regulation of cellular organization. Cytokinetics' R&D efforts aim to address pharmaceutical needs in cancer, cardiovascular and infectious diseases and feature proprietary Cytometrix(TM) cellular phenotyping technologies designed to industrialize cell biology for increased speed and productivity in drug discovery and development. Cytokinetics and GlaxoSmithKline have entered into a broad strategic collaboration to discover, develop and commercialize novel small molecule therapeutics targeting mitotic kinesins for applications in the treatment of cancer and other diseases. Cytokinetics and GlaxoSmithKline are conducting Phase I studies with the first novel anti-cancer drug candidate emerging from the collaboration and intend to expand clinical development upon completion of these studies. Additional information about Cytokinetics can be obtained at www.cytokinetics.com. ABOUT ASTRAZENECA AstraZeneca is a major inxxxxxxxxxxx xxxxxxxxre business engaged in the research, development, manuf...
Technologies. Subject to the terms and conditions of this Agreement, at the Closing, Seller will sell, convey and transfer to Buyer, and Buyer will purchase from Seller, the following Technologies (the "Technologies"): All of Seller's right, title and interest to the Mariah Internet Protocol Telecomputing Project, the MindWalker Series, the Crayon Crawler Browser, the Spirit 32 Voice Mailer and all of the tradenames and copyrights associated with the names "Crayon Crawler," "Mindwalker" and "Mariah." Buyer takes said Technologies "as is" without warranty of any kind either expressed or implied.
Technologies. Flagship has also adopted a series of cutting edge technologies that enable us to continually monitor the quality of service we’re providing: • Biometric time keeping systems • Restroom FOB tracking system • Proprietary Inspection SystemWork Order and Periodic Work Order Systems.
Technologies. Annex 8(a) hereto correctly describes technologies used in the Business included in the Contributed Assets (the "TECHNOLOGIES"), which AL1 owns or has licenses to.
Technologies. Due to the fact that the frequency coordination situation of GSM vs. GSM has already been regulated, the following coordination situations are regulated in this Technical Arrangement: • GSM system vs. broadband systems • broadband systems vs. broadband systems With regard to these relationships between the narrow band GSM and the broadband system and between broadband systems, the applied principles are the following:
Technologies. Only solar electric photovoltaic (PV) facilities qualify as Eligible Facilities. The Seller is responsible for registering and maintaining their Facility as RPS compliant with the California Energy Commission (CEC). Refer to the CEC RPS Eligibility Guidebook1 for the latest certification requirements. QUALIFIED FACILITY COMPONENTS Only photovoltaic modules that are certified by a nationally recognized testing laboratory are eligible.2 All photovoltaic modules must be certified as meeting the requirements of the Underwriters Laboratory Standard (UL) 1703. For custom photovoltaic modules not certified by UL 1703, parties may seek certification by the Los Angeles Department of Building and Safety Materials Test Lab (xxxx://xxxxx.xxx). Facilities will not be approved by LADWP inspectors until proof of certification is received by LADWP. All inverters must be certified by a nationally recognized testing laboratory for safe operation and must be certified as meeting the requirements of UL 1741. LADWP reserves the right to adopt additional codes, standards, and conditions, prior to execution, at its sole discretion. 1 The CEC RPS Eligibility Guidebook can be found at: xxxx://xxx.xxxxxx.xx.xxx/renewables/documents/ 2 The CEC maintains a list of certified modules that can be obtained from the CEC website at: xxxx://xxx.xxxxxxxxxxxxxxxxx.xx.xxx PARCEL LIMITATIONS The renewable generator(s) that constitutes the Facility shall be within the boundaries of one legal parcel, identified by Appendix D by Assessors Parcel Number (APN).
AutoNDA by SimpleDocs
Technologies. 2.1.1 General Packet Radio Service (“GPRS”) GPRS is a specification for data transfer on TDMA and GSM networks with speeds of up to one hundred seven (107) Kbps. GPRS has wireless data coverage in most major metropolitan areas.
Technologies. The specific objectives are to: (i) reduce electricity consumption by implementing RE and EE measures; (ii) reduce Green House Gases (GHG) emissions from liquid fossil fuels used for power generation and transport; and (iii) increase institutional capacity for the management of RE and EE programs.
Technologies. These organizations shall be enabled through proposed initiatives to sit at the heart of innovation structures (i.e. testbeds and competence centers) and build around them emerging, industrial ecosystems. These ecosystems will bring together Greek industrial organizations, Industry 4.0 producers and/or academic/ research institutions and will establish close collaboration for co-designing tailored, innovative Industry 4.0 solutions and for addressing key challenges that the Industry faces. With regards to the Industry 4.0 “supply” side, we have also identified three different groups of stakeholders that shall be enabled by the Industry 4.0 strategy to accelerate their efforts for the production of commercialized Industry 4.0 solutions: • ICT Services Organizations, focused on Industry 4.0 solutions for industrial/manufacturing SMEs/ mid-caps This group of organizations, with high maturity and expertise demonstrated on ICT and Industry
Time is Money Join Law Insider Premium to draft better contracts faster.